57 (PB045): Individualised schedule optimisation improves rates and severity of anaemia in patients (pts) treated with lunresertib (lunre), a PKMYT1 inhibitor, and camonsertib (cam), an ATR inhibitor, in the phase I MYTHIC study (NCT0485565)

Saved in:
Bibliographic Details
Published in:European journal of cancer (1990) 2024-10, Vol.211, p.114584, Article 114584
Main Authors: Hojgaard, M., Yap, T.A., Lee, E.K., Weiss, M.C., Lheureux, S., Simpkins, F., LoRusso, P., Carneiro, B.A., Moy, R.H., Aguado-Fraile, E., Sethuraman, S., Soria-Bretones, I., Liu, Y., Sun, X., Hawkey, N., Basciano, P., Unger, T.J., Bacqué, E.S., Schram, A.
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0959-8049
DOI:10.1016/j.ejca.2024.114584